Menu
Search
|

Menu

Close
X

Imprimis Pharmaceuticals Inc IMMY.OQ (NASDAQ Stock Exchange Capital Market)

1.74 USD
+0.00 (+0.29%)
As of Feb 16
chart
Previous Close 1.73
Open 1.75
Volume 21,886
3m Avg Volume 128,449
Today’s High 1.79
Today’s Low 1.72
52 Week High 4.68
52 Week Low 1.35
Shares Outstanding (mil) 20.54
Market Capitalization (mil) 35.63
Forward P/E --
Dividend (Yield %) -- ( -- )

LATEST NEWS

ADVERTISEMENT

RECOMMENDATION

No Data Available
Sell Hold Buy

KEY STATS

Revenue (mm, USD)
FY17
19
FY16
20
FY15
10
EPS (USD)
FY17
-0.481
FY16
-1.509
FY15
-1.658
*Note: Units in Millions of U.S. Dollars
**Note: Units in U.S. Dollars

KEY RATIOS

Price to Earnings (TTM)
vs sector
--
34.43
Price to Sales (TTM)
vs sector
1.41
8.57
Price to Book (MRQ)
vs sector
9.34
5.14
Price to Cash Flow (TTM)
vs sector
--
25.75
Total Debt to Equity (MRQ)
vs sector
409.02
15.12
LT Debt to Equity (MRQ)
vs sector
394.02
11.85
Return on Investment (TTM)
vs sector
-85.34
13.54
Return on Equity (TTM)
vs sector
-465.67
14.80

EXECUTIVE LEADERSHIP

Robert Kammer
Chairman of the Board, Since 2012
Salary: --
Bonus: --
Mark Baum
Chief Executive Officer, Director, Since 2012
Salary: $327,456.00
Bonus: $203,980.00
Andrew Boll
Chief Financial Officer, Secretary, Since 2015
Salary: $154,125.00
Bonus: $95,000.00
John Saharek
Chief Commercial Officer, Since 2015
Salary: --
Bonus: --
Stephen Austin
Independent Director, Since 2012
Salary: --
Bonus: --

COMPANY PROFILE

Sector: Healthcare
Industry: Biotechnology & Medical Research
Address:

12264 El Camino Real Ste 350
SAN DIEGO   CA   92130-0001

Phone: +1858.7044042

Imprimis Pharmaceuticals, Inc. (Imprimis) is engaged in the development, production and dispensing of compounded pharmaceuticals. The Company operates through the business of developing drug therapies and providing such therapies through sterile and non-sterile pharmaceutical compounding services segment. The Company, through its Imprimis Cares program, owns, markets and dispenses a portfolio of compounded therapeutic in several therapeutic areas, including ophthalmology, urology, otolaryngology and infectious diseases. The Company is also developing Custom Compounding Choice business, which is focused on developing and dispensing a portfolio of non-proprietary compounded drugs for humans and animals in therapeutic areas that may be overlooked by commercial pharmaceutical companies. The Company also offers customizable compounding products that consist of sterile injectable and non-sterile integrative medicine therapies that are used in various therapeutic areas.

SPONSORED STORIES